Objective: Trans-apical aortic valve implantation (TA-AVI) using the Edwards SAPIEN TM prosthesis has evolved to a routine procedure for selected high-risk elderly patients. In rare cases, misplacement of the SAPIEN TM valve (too low a position), dysfunction of the leaflets or perforation of the interventricular septum (ventricular septal defect, VSD) occurs and requires immediate implantation of a second prosthesis within the first one. Results of this 'bailout' maneuver have not been reported yet. Methods: Of 305 TA-AVI procedures, 15 patients required a second prosthesis due to dysfunctional leaflets (n = 6), low position (n = 7), or VSD (n = 2). Mean age was 82.5 AE 1.3 years, mean logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) was 45.5 AE 5.4, and Society of Thoracic Surgeons (STS) Score was 13.5 AE 1.5. Results: All second SAPIEN TM valves could be implanted successfully within the first one. The second prosthesis solved leaflet dysfunction, sealed the VSD (lower position of the second prosthesis), or corrected the initial misplacement (higher position of the second prosthesis) in all patients. Within 30 days, four patients died (low cardiac output n = 3, all with preoperative ejection fraction (EF) <35%; intestinal ischemia n = 1). Intra-operative echocardiogram and angiogram revealed mild paravalvular leak in three and none/trace in 12 patients. Transvalvular gradients were low despite the implantation of the second valve (P max /mean 13.7 AE 4.3/6.4 AE 2.0). Conclusion: Placement of a second SAPIEN TM valve is a valuable 'bailout' technique in case of VSD, dysfunctional leaflets, or too low placement of the first prosthesis. The technique leads to an excellent functional result with low transvalvular gradients. The simple, straight, tubular stent design of the SAPIEN TM prosthesis may be the ideal design for such valve-in-valve procedures. #
Introduction
Trans-catheter aortic valve implantation (T-AVI) has evolved to a routine procedure in specialized centers to treat selected high-risk elderly patients. The Edwards SAPIEN TM (Edwards Lifesciences, USA) prosthesis is designed for either retrograde transfemoral (TF-AVI) or antegrade trans-apical (TA-AVI) implantation. At present, there is no evidence proving the superiority of the one or the other approach. After initial learning, results now seem to have stabilized and recently results from a larger multicenter series have been reported [1] .
In the vast majority of patients, the prosthesis can be implanted as intended, leading to a good valve function.
However, misplacement of the device may occur leading to severe paravalvular or central aortic insufficiency (AI). In addition, severe AI might be present due to leaflet dysfunction on rare occasions.
Implantation of a second SAPIEN TM prosthesis during the same procedure has been reported as a potential bailout technique in these scenarios. Functional results and clinical outcomes of the valve-in-a-valve (VinV) concept as a procedural rescue option have not been reported yet in a larger patient cohort.
Methods

Patients
Since February 2006, a total of 305 patients were treated using the Edwards SAPIEN TM prosthesis (Fig. 1 ). All valves were implanted using the antegrade trans-apical approach (TA-AVI). Out of the total series, in 15 patients a second SAPIEN TM prosthesis (VinV) was implanted as a procedural rescue technique. These patients form the study cohort. Mean age was 82.5 AE 1.3 years, mean logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation) was 45.5 AE 5.4, and Society of Thoracic Surgeons (STS) Score was 13.5 AE 1.5. Preoperative characteristics of the patients are presented in Table 1 .
All patients were discussed in an interdisciplinary team to decide the best treatment option in each individual patient. In addition to an informed consent, all treatment options including conventional surgery were discussed with the individual patients.
Implantation technique
All procedures were performed under fluoroscopic guidance (Artis zeego, Siemens AG, Germany) in a fully equipped hybrid room. In addition, transesophageal echocardiography (TEE) was always available and all procedures were performed under general anesthesia. Prior to skin incision, a percutaneous femoral safety net consisting of an arterial sheath and a venous wire was placed [2] . Cardiopulmonary bypass (CPB) was always available on standby. All valve implantations were performed by a specialized team involving cardiac surgeons, cardiologists, and cardiac anesthetists.
Trans-apical access was gained as previously described in detail [3] .
Optimal angulation of the C-arm of the fluoroscopic system was established, if available, with the help of the DynaCT [4] technology.
Valve implantation itself was performed as previously described in detail [3] , in a stepwise manner during a final angiography allowing for final adjustments during balloon inflation.
For the implantation of the second SAPIEN TM prosthesis, a similar technique and the same size valve were used. Positioning was performed using the radiopaque stent of the first valve as a landmark. The implantation of the VinV was carried out with a relatively slow balloon inflation in a pronounced stepwise manner to allow for a controlled final positioning of the second prosthesis within the stent of the first implanted SAPIEN TM . After routine apical and chest-wall closure, all patients were transferred to the intensive care unit or the postanesthetic care unit for early extubation following an ultrafast-track protocol.
Statistics
For statistical analysis, data were 100% complete. Continuous variables are expressed as mean plus standard deviation for Gaussian distribution and otherwise as median values and ranges. Categorical data are given as proportions.
Follow-up
All patients had echocardiographic examination before discharge, and follow-up data are available up to 6 months.
Results
Implantation of a second SAPIEN
TM 'rescue' prosthesis as a VinV was performed for three different failure mechanisms.
'Too low' initial position
In seven patients, the first prosthesis had been implanted in a borderline or clearly too-low position resulting in moderate or severe paravalvular leakage due to insufficient covering of the aortic annulus or a trans-stent leak. Low positioning was attempted in all cases due to low insertion of the coronary arteries. A second SAPIEN TM prosthesis was successfully implanted in all seven patients in a slightly higher (in direction of the ascending aorta) position. One patient required temporarily CPB support during VinV implantation. The second valve resulted in a good functional result in all patients, with a mild (1+) residual paravalvular leak present in two and none/trace in five patients. 
'Dysfunctional leaflets/central leak' after initial valve implantation
Despite a satisfactory intraannular position of the first SAPIEN TM valve, severe central AI was present in six patients. TEE demonstrated a severe central leak in contrast to none or trace paravalvular leak in these patients (Video 1). Increase of the arterial pressure by norepinephrine and attempts to manipulate the leaflets using the pigtail catheter in the aortic root were not successful. Finally, a second 'rescue' valve was implanted in all six patients in a slightly higher position to treat the potentially present phenomenon of stillactive native leaflets disturbing the free diastolic flow pattern. Fig. 3 demonstrates the implantation sequence. One of those six patients accidentally received an initially 'upside-down' crimped valve, which leads to massive aortic incompetence and required temporary CPB support. This patient had an uneventful further course after receiving a second valve.
The second valve resulted in a good functional result in all patients, with a mild (1+) residual paravalvular leak present in one and none/trace in five patients. Except for one patient who required temporary CPB support, all VinV implantations were performed under stable hemodynamical conditions off pump. TEE revealed fully functional leaflets after VinV implantation in all six patients without relevant central leak (Video 2).
Ventricular septal defect (VSD) after initial valve implantation
In two other patients, a ventricular septal defect (VSD) was visible on angiographic control immediately after initial valve implantation (Fig. 4) . In both patients, a second 'rescue' valve was implanted following the idea that the proximal covered part of the SAPIEN TM stent might seal the VSD in the left-ventricular outflow tract. VinV implantation could be performed off pump in both patients and completely sealed the VSD in both cases.
Outcome
Four patients died within the first 30 days after the procedure. Causes of death were intestinal ischemia in one patient on postoperative day (pod) 1, low output in two patients both with preoperative EF <35% (pod 2 and 10), and a sudden cardiac suffered by one patient on pod 5. In all patients, TEE demonstrated good (unchanged) valve function and there were no clinical signs of new coronary ischemia (Table 2) .
New-onset permanent pacemaker implantation due to atrioventricular block was not required in any patient. Aortic dissection, annular tear, coronary impingement, stroke, or valve embolization did not occur. Table 3 summarizes the 30-day outcome.
Six-month follow-up
One additional patient died after initial hospital discharge in good condition due to unclear reasons on postoperative day 83. All other patients demonstrated stable valve function during 6-months' follow-up.
Discussion
The SAPIEN TM prosthesis requires very precise positioning to achieve good valve function. Although this can be achieved [ Similarly, the VinV technique as a bailout option is also feasible in case of a malpositioned or dysfunctional CoreValve TM (Medtronic Inc., USA) prosthesis [6] . A few specific issues of the VinV rescue concept should be taken into consideration. The SAPIEN TM valve has a stent profile of approximately 1 mm. Hence, after the first valve has been implanted, the annulus is 'shrinked down' by 2 mm. If pronounced oversizing was present in the first place, a smaller valve size or a balloon filled with 1 ml less volume should be chosen for the second valve. On the other hand, this mechanism can be used in case of severe paravalvular leak and suspected 'too large' annulus after first valve implantation. The second valve with the same size would then overextend the first one and at the same time would increase the radial forces, thus eliminating much of the 'recoil' effect [7] . Care should be taken not to 'overcorrect' initial valve malposition. The concept of the VinV only works if the leaflets of the first valve are fully covered by the stent of the second valve. In case of insufficient overlapping, the second valve might not catch the leaflets of the first valve resulting in severe central leak due to an impaired diastolic flow pattern. To avoid delay of the implantation of the second valve and to avoid hemodynamic deterioration due to a prolonged period of severe AI, the delivery catheter should be handed over for re-preparation to the person crimping the valve immediately when the option of a VinV is discussed in the team.
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If dysfunction or immobility of leaflets is suspected, freeing a 'stucked' leaflet can be attempted by moving the pigtail catheter in the aortic root. A truly immobile leaflet [8] is a rare complication that might be associated with the crimping process. It seemed that in some cases of dysfunctional leaflets, the native leaflets of the aortic valve were still 'active' above the leaflets of the first SAPIEN TM valve, blocking free diastolic flow onto the leaflets of the transcatheter valve. Although it might not be obvious on fluoroscopy, this observation indicates the need for a higher valve implantation in case of a VinV decision. Discrimination of true dysfunctional vs 'stucked' leaflets due to insufficient diastolic flow because of a borderline low SAPIEN TM position with the native aortic leaflets still active is often not feasible. However, a second 'rescue' valve roughly 30% higher should solve both failure modes.
In both patients, where a VSD was visible after valve implantation, oversizing has not been performed too aggressively (3 mm) and none of the patients presented with unusually severe calcifications. On the other hand, both patients with VSD were relatively old (88 and 87 years), in whom fragility of cardiac tissue might be present partially explaining the phenomenon, but the specific reason for the VSD remains somehow unclear. Irregular calcifications that were squeezed into the membraneous septum will have been the most reasonable cause.
The rate of two trans-catheter valve implantations within one procedure has been reported with 2.1% for the SAPIEN TM prosthesis [1] and with 2.6% for the CoreValve TM device [9] . By contrast, the rate of a procedural second 'rescue' valve was 4.9% in our series. We believe that aggressive treatment of any residual paravalvular or central AI more than mild (>1/4) should be discussed in the team in every patient. The majority of TAVI patients could also undergo 'high-risk' conventional minimally invasive aortic valve replacement with known excellent functional results. At present, there is no trial proving the benefit of TAVI regarding survival, although a recent publication showed at least as good results as conventional surgery [10] . Hence, an aggressive attitude toward residual AI is mandatory to match the basic idea of TAVI.
Initially, transvalvular gradients after VinV implantation were of concern. Surprisingly, measured gradients were consistently low throughout the reported series. Still, longterm durability of such a VinV construct is not proven, but, from a theoretical aspect there should be no difference compared to a 'single' valve. Although not proven in a large number of patients, one report of a VinV CoreValve case suggests good midterm durability with follow-up extending up to 3 years [11] .
Conclusion
Placement of a second 'rescue' SAPIEN TM valve is a valuable 'bailout' technique in case of VSD, dysfunctional leaflets, or too low placement of the first prosthesis. The technique leads to an excellent functional result with low transvalvular gradients. The simple, straight, tubular stent design of the SAPIEN TM prosthesis may be the ideal design for such VinV procedures. 
